The statements contained in this press release on matters that are not historical facts are forward-looking statements within the meaning of applicable securities legislation, including, but not limited to, quotes from Xencor`s President and Chief Executive Officer; the results of the collaboration with MorphoSys and Incyte, including the ability to cooperate to generate new clinical knowledge, accelerate development timelines and promote patient care; the ability of the proposed combination therapy to improve response rates and reach more patients in areas of unmet need; and the timing and success of the Phase 1/2 study and several Phase 1b studies under the agreement. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or results and the timing of events to differ materially from those implied in such statements, and therefore such statements should not be considered as warranties of future performance or results. These risks include, but are not limited to, risks related to the process of detecting, developing, manufacturing and marketing safe and effective drugs for use as human therapy drugs, as well as other risks described in Xencor`s public securities statements. Xencor`s Annual Report on Form 10-K for the year ended December 31, 2019 and in Xencor`s subsequent submissions to the Securities and Exchange Commission. All forward-looking statements are based on Xencor`s current information and beliefs, as well as Xencor`s assumptions. We advise you not to place too much reliance on these forward-looking statements, which apply only at the time of this publication. These warnings are issued in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are limited in their entirety by this disclaimer and Xencor assumes no obligation to revise or update this press release to reflect events or circumstances after the date of this press release, except as required by law. Christine Chiou Senior Director, Investor Relations Tel: +1 302 274 4773 email@example.com In January 2020, MorphoSys and Incyte entered into a cooperation and licensing agreement for the development and commercialization of Tafasitamab worldwide. Monjuvi is marketed jointly by Incyte and MorphoSys in the United States.
Incyte has exclusive marketing rights outside the United States. As part of the agreement, the companies plan to initiate a Phase 1/2 study to evaluate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL. In addition, the companies plan to evaluate the combination in recurrent or refractory fl and first-line DLBCL in several Phase 1b studies. MorphoSys and Incyte will provide Tafasitamab to Xencor-sponsored and funded studies, which will be conducted in North America, Europe and Asia-Pacific. MorphoSys Forward-Looking Statements This communication contains certain forward-looking statements about the MorphoSys Group, including expectations regarding the licensing agreement for Tafasitamab, the continued clinical development of tafasitamab, interactions with licensing authorities and expectations regarding applications for authorization and possible authorizations for Tafasitamab, as well as the potential future commercialization of Tafasitamab. . . .